List of Excipients in Branded Drug AZEDRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Progenics Pharmaceuticals Inc	AZEDRA	iobenguane i-131	71258-015	SODIUM ASCORBATE	1969-12-31
Progenics Pharmaceuticals Inc	AZEDRA	iobenguane i-131	71258-015	SODIUM GENTISATE	1969-12-31
Progenics Pharmaceuticals Inc	AZEDRA	iobenguane i-131	71258-015	WATER	1969-12-31

Last updated: August 8, 2026

AZEDRA is a targeted radiopharmaceutical containing iobenguane I 131 for adults with iobenguane scan-positive, unresectable or metastatic pheochromocytoma or paraganglioma. Its excipient opportunity is concentrated in radiolysis control, metal-ion management, isotonicity, low-volume sterile filling, container closure, and decentralized radiopharmacy handling. The product has no biosimilar pathway, while future competition is more likely to arise from alternative MIBG products, hospital-compounded radiopharmaceuticals, or new radioligand therapies than from conventional generic tablets or injectables.

AZEDRA Excipient Strategy and Commercial Opportunities

What is AZEDRA and how does its formulation work?

AZEDRA, or iobenguane I 131, is an intravenously administered radioactive drug approved by the U.S. Food and Drug Administration in July 2018. It is used for adult patients with iobenguane scan-positive, unresectable locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy [1].

The formulation combines:

• Iobenguane I 131 as the radioactive active ingredient
• Sodium chloride for isotonicity
• Ascorbic acid as an antioxidant and radiolysis-control agent
• Edetate disodium as a chelating agent
• Water for injection as the vehicle

AZEDRA is supplied as a dosimetric dose and a therapeutic dose. The treatment is administered through a specialized nuclear medicine workflow that includes radiation-safety controls, patient hydration, thyroid blockade, renal monitoring, and radiation exposure management [1].

The formulation problem differs from that of a conventional injectable. The principal risks are not only chemical degradation and microbial contamination. They also include:

1. Radiolytic degradation caused by beta and gamma emissions.
2. Formation of radioactive or nonradioactive impurities.
3. Metal-catalyzed oxidation.
4. Adsorption to vial, stopper, tubing, or syringe surfaces.
5. Product loss during transfer in a radiopharmacy.
6. Maintaining sterility and dose accuracy under short handling windows.

What excipients are used in AZEDRA?

The publicly disclosed excipient platform is a conventional low-complexity parenteral system adapted for a radiopharmaceutical. The key components are summarized below.

Excipient	Functional role	Commercial relevance
Ascorbic acid	Antioxidant and radiolysis-control agent	High relevance to radioactive injectable stability
Edetate disodium	Chelates trace metals that can accelerate degradation	Relevant to impurity control and formulation robustness
Sodium chloride	Isotonicity adjustment	Commodity component with low differentiation
Water for injection	Sterile vehicle	Required for parenteral manufacture

The commercial value does not sit primarily in the individual excipients. It lies in the concentration range, order of addition, pH control, sterilization strategy, vial compatibility, hold time, and performance after radioactive labeling.

The product labeling identifies excipient content and administration controls, but it does not disclose the full manufacturing design space, including mixing sequence, oxygen exposure limits, maximum permissible hold time, or container-closure qualification data [1].

How does AZEDRA’s excipient strategy control radiolysis?

Radiolysis is the principal formulation challenge. Radioactive iodine can generate reactive species in the drug solution, including free radicals and oxidizing products. These species can degrade iobenguane, alter radiochemical purity, and increase the fraction of free radioactive iodine.

Ascorbic acid is strategically important because it can consume oxidative species generated during radioactive decay. Its value depends on:

• Concentration relative to the radioactive dose
• Product age and decay profile
• Oxygen content in the vial headspace
• Temperature during storage and shipment
• Surface area exposed during transfer
• Compatibility with the stopper and administration system

Edetate disodium provides a second layer of protection. Trace metals can catalyze oxidation and accelerate degradation. Chelation can reduce that pathway, although the chelator must remain compatible with the active ingredient, radioactive iodine chemistry, container closure, and patient administration requirements.

A commercially attractive excipient package for AZEDRA-like products would therefore focus on combined antioxidant and chelation performance rather than a single additive. Suppliers could develop:

• Low-metal excipient grades
• Radiopharmaceutical-grade ascorbic acid
• Optimized antioxidant-chelator systems
• Oxygen-reduced sterile solutions
• Low-extractables packaging systems
• Stabilizer systems validated across the full radioactive shelf-life window

What formulation patents protect AZEDRA?

The public commercial protection for AZEDRA is likely to be more important at the active-ingredient, treatment-method, manufacturing, and radiopharmaceutical-use levels than at the basic excipient level.

A formulation competitor should assess five categories of rights:

Patent category	Potential relevance to AZEDRA competition
Iobenguane I 131 composition patents	May cover radioactive drug composition or purity profile
Method-of-treatment patents	May cover dosing, patient selection, or treatment sequencing
Manufacturing patents	May cover iodination, purification, or radioactive handling
Formulation patents	May cover antioxidant, chelator, pH, or stability combinations
Delivery and handling patents	May cover vial, shielding, transfer, or administration systems

A basic sodium chloride and antioxidant formulation is generally difficult to protect broadly unless the patent demonstrates an unexpected stability result, a defined radiochemical-purity threshold, or a specialized manufacturing advantage.

The strongest excipient-related claims would likely require a narrow combination such as:

• Iobenguane I 131
• A defined concentration of ascorbic acid
• A specified chelator concentration
• A controlled pH range
• A defined radiochemical-purity level after radioactive decay or storage
• A specific container-closure system
• A manufacturing process that limits free iodine or radiolytic impurities

Public FDA approval materials and the Orange Book should be used to identify listed patents, pediatric exclusivity, and regulatory exclusivity. The FDA label itself does not establish that all formulation know-how is disclosed in patent filings [1,2].

When does AZEDRA lose exclusivity?

AZEDRA was approved on July 30, 2018, and received orphan-drug designation. Orphan-drug exclusivity generally runs for seven years from approval, subject to statutory exceptions. The principal U.S. orphan exclusivity period therefore reached its scheduled endpoint in July 2025, based on the approval date [1,3].

Protection or regulatory event	Date or status
FDA approval	July 30, 2018
Orphan-drug exclusivity	Scheduled to run through July 30, 2025
New chemical entity exclusivity	Depends on FDA classification and Orange Book records
Patent expiry	Must be determined from the applicable U.S. patent family
Biosimilar exclusivity	Not applicable
Generic entry	Dependent on patent, regulatory, manufacturing, and radiation-handling barriers

Loss of orphan exclusivity does not create an automatic generic launch opportunity. A competitor still must address the abbreviated new drug application or other applicable pathway, demonstrate pharmaceutical equivalence where required, obtain access to radioactive iodine manufacturing, and meet drug-product and radiation-safety requirements.

What FDA regulatory pathway would a competing AZEDRA product use?

A conventional ANDA may be difficult because AZEDRA is a radioactive injectable with specialized manufacturing and quality attributes. The relevant pathway would depend on the product’s active ingredient, dosage form, radioactive content, formulation, and proposed labeling.

Potential regulatory routes include:

• An ANDA for a pharmaceutically equivalent product
• A 505(b)(2) application for a modified formulation, manufacturing process, or dosage presentation
• A full 505(b)(1) application for a materially different radioactive therapeutic
• A supplemental application for an approved product with a new indication or dosing method

A 505(b)(2) strategy could be commercially useful for a product that changes:

• Antioxidant concentration
• Chelator system
• Vial size
• Dose presentation
• Ready-to-use configuration
• Shelf-life profile
• Radiopharmacy preparation requirements

The principal technical hurdle is not merely matching the listed excipients. The applicant would need to establish radiochemical purity, chemical purity, sterility, endotoxin control, dose uniformity, stability under decay, and compatibility with administration equipment.

Are Paragraph IV challenges likely for AZEDRA?

A Paragraph IV challenge is possible after the relevant regulatory exclusivity expires, but the commercial incentive is more limited than for a high-volume oral medicine.

A challenger would need to evaluate:

• Listed Orange Book patents
• Expired or unlisted formulation patents
• Method-of-use claims
• Patent-term adjustment
• Pediatric exclusivity
• Patent certifications required for the proposed labeling
• Availability of radioactive iodine manufacturing capacity
• Demand concentration in specialist treatment centers

The principal risk is that a competitor may successfully challenge a formulation or method patent but still face high development and distribution costs. AZEDRA requires a narrow clinical market, specialized treatment centers, radiation-safety infrastructure, and controlled supply logistics.

A successful Paragraph IV product could obtain 180-day first-filer exclusivity if the statutory conditions are satisfied. The value of that exclusivity would depend on whether the challenger can supply a product at scale and whether the market supports more than one radiopharmaceutical supplier.

What manufacturing and intellectual-property barriers affect AZEDRA competition?

Radioiodination and purification

Iobenguane I 131 requires radioactive iodine handling, chemical synthesis, purification, quality testing, and shipment within a limited time period. Manufacturing rights may cover precursor chemistry, radioiodination conditions, impurity removal, or release testing.

Radiation-resistant packaging

The vial, stopper, shield, and transport container must maintain integrity throughout radioactive decay and distribution. Packaging suppliers with validated low-extractables, low-adsorption, and radiation-compatible systems can create meaningful switching costs.

Short operational windows

Radioactive products lose activity through physical decay. Distribution and pharmacy preparation must be coordinated with the prescribed dose. Excipient systems that extend usable hold time or reduce radiochemical impurity formation can improve dose utilization and reduce discarded inventory.

Specialized quality systems

A competitor must demonstrate compliance with sterile manufacturing rules, current good manufacturing practice, radioactive-material controls, and applicable U.S. Pharmacopeia requirements. These requirements limit the number of credible entrants.

What commercial opportunities exist for AZEDRA excipient suppliers?

The most attractive opportunities are platform technologies that apply to multiple radiopharmaceuticals, not a single AZEDRA copy.

Radiolysis stabilizer systems

Suppliers can offer antioxidant-chelator packages for iodine-131, lutetium-177, yttrium-90, actinium-225, and other therapeutic radionuclides. The commercial proposition is improved radiochemical purity, longer usable hold time, or reduced product loss.

Low-metal excipient supply

Trace-metal control is important when formulation degradation is metal-catalyzed. Pharmaceutical manufacturers may pay a premium for low-metal grades with tighter elemental impurity specifications and validated lot-to-lot consistency.

Sterile ready-to-use excipient concentrates

Radiopharmacies may benefit from sterile, standardized stabilizer solutions that reduce manual compounding steps. The product must be compatible with radioactive handling procedures and supported by validated stability data.

Container-closure systems

Vial and stopper systems with low adsorption, low extractables, and radiation compatibility may offer a higher-value opportunity than commodity excipients. This is particularly relevant where product is held in the vial for extended periods before administration.

Automated dispensing compatibility

Preconfigured vials, syringes, and transfer assemblies can reduce dose loss and operator exposure. A supplier that integrates excipient formulation with automated dispensing hardware may obtain stronger commercial differentiation than an excipient-only supplier.

Stability analytics

Analytical packages for free iodine, radiochemical purity, degradation products, and metal contamination can support both AZEDRA-like products and broader radiopharmaceutical portfolios. Methods that work within short radioactive half-lives have high operational value.

How does AZEDRA compare with other radiopharmaceutical commercial opportunities?

Attribute	AZEDRA	Lutetium-177 radioligands	Actinium-225 products	Conventional injectable
Main formulation risk	Radiolysis and free iodine	Radiolysis, chelation, radiometal stability	Severe radiolysis and daughter-nuclide effects	Chemical and microbial stability
Excipient differentiation	Moderate	High	Very high
Low to moderate
Market scale	Narrow orphan oncology market	Broader and expanding	Early-stage and specialty	Broad
Manufacturing complexity	High	High	Very high	Moderate
Biosimilar pathway	None	None	None	Sometimes applicable
Key supplier opportunity	Stabilizers and packaging	Chelators and radiolysis control	High-performance stabilization	Standard excipients

AZEDRA is a useful reference product for an excipient supplier because its formulation requirements are representative of therapeutic radiopharmaceutical development. The larger opportunity may be to build a validated excipient and packaging platform that can be licensed across several radionuclide products.

What is the litigation and settlement outlook for AZEDRA?

Publicly visible litigation risk is likely to center on patent scope, commercial manufacturing, and competing radiopharmaceutical technologies rather than conventional generic substitution. A potential dispute could involve:

• Patent validity or claim construction
• Noninfringement of formulation claims
• Method-of-use claims for pheochromocytoma or paraganglioma
• Radioiodination and purification processes
• Trade secrets relating to radiochemical stability
• Licensing rights for manufacturing or distribution

Settlement terms in this market could include delayed entry, geographic restrictions, supply agreements, authorized-generic arrangements, or cross-licensing of radiopharmaceutical manufacturing technology. For an excipient supplier, freedom-to-operate review should distinguish a proprietary excipient composition from the use of a commercially available excipient in a radioactive product.

What is the commercial exposure associated with AZEDRA?

AZEDRA is a specialty orphan oncology product. Revenue exposure is concentrated in a small number of nuclear medicine and oncology centers rather than a broad retail or hospital formulary market.

The main commercial sensitivities are:

• Number of qualified treatment centers
• Patient identification through MIBG imaging
• Reimbursement for inpatient or outpatient administration
• Radiation-safety costs
• Manufacturing capacity
• Radioactive shipment reliability
• Dose wastage caused by scheduling changes
• Competition from peptide receptor radionuclide therapies and other targeted radiotherapies

Excipient improvements that reduce wastage, extend operational flexibility, or simplify administration may have greater economic value than small reductions in raw-material cost.

Key Takeaways

• AZEDRA uses a simple parenteral excipient system built around ascorbic acid, edetate disodium, sodium chloride, and water for injection.
• The central formulation challenge is radioactive degradation, not conventional solubility.
• Antioxidant-chelator systems, low-metal excipients, radiation-compatible closures, and sterile ready-to-use components offer the strongest commercial opportunities.
• AZEDRA’s seven-year orphan-drug exclusivity was scheduled to expire in July 2025, but patent and regulatory barriers may still delay competition.
• No biosimilar pathway applies because AZEDRA is a radioactive small-molecule drug.
• A competitor is more likely to use an ANDA or 505(b)(2) strategy than to develop a biosimilar.
• The highest-value opportunity is a radiopharmaceutical excipient platform that can support AZEDRA-like products and newer lutetium-177 or actinium-225 therapies.

FAQs

Can a new excipient formulation extend AZEDRA’s shelf life?

Potentially, but the sponsor would need to establish radiochemical purity, chemical stability, sterility, container compatibility, and performance across radioactive decay. A new formulation may require a regulatory supplement or a new application depending on the extent of the change.

Does AZEDRA require a chelator like lutetium-177 radioligands?

No. Iobenguane I 131 is an iodine-labeled small molecule and does not require a metal-chelating ligand for radionuclide attachment. Edetate disodium functions as a formulation chelator for trace metals rather than as the radionuclide-binding pharmacophore.

Can hospital pharmacies compound an AZEDRA substitute?

Routine hospital compounding does not create a straightforward substitute for an FDA-approved therapeutic radiopharmaceutical. Radioactive iodine handling, sterile manufacture, quality testing, labeling, and radiation-safety requirements create substantial operational barriers.

Which excipient has the greatest strategic value in AZEDRA?

Ascorbic acid has the clearest direct role in controlling oxidative radiolysis. The highest commercial value, however, may come from the combined stabilizer system and its interaction with the container closure, manufacturing process, and radioactive handling period.

Is AZEDRA exposed to biosimilar competition?

No. Biosimilar rules apply to biological products. AZEDRA is a radioactive small-molecule drug, so competitive entry would follow small-molecule drug or radiopharmaceutical pathways.

References

1. U.S. Food and Drug Administration. (2018). AZEDRA (iobenguane I 131) injection prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity.